A Phase 2, Randomized, Double-blind, Placebo-controlled, add-on Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus Receiving Sitagliptin
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs DS-8500 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 10 Jun 2017 Biomarkers information updated
- 11 Nov 2016 Status changed from active, no longer recruiting to completed.
- 25 Aug 2016 Status changed from recruiting to active, no longer recruiting.